, a cancer-fighting gene therapy company, has seen its initial public offering price slink lower and lower. Welp, you hear that? That's a thud. This morning, underwriter
priced the 4-million-share offering at $8 a share, the low end of a previously announced range between $8 and $10. In fact, that range was a reduction from the August projection of $12 to $14 a share. Back then, Cowen wanted to offer 5 million shares.
The stock will start to trade today.